News 06.11.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data supporting an attractive therapeutic window for...
News 05.11.2026 Schlieren-Zurich, Switzerland, 05 November 2026 – Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels. The trial is evaluating lead candidate TOP-N53 for the treatment of systemic sclerosis-associated digital ulcers....
News 05.11.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold presentations on its lead Radio-DARPin candidate MP0712, co-developed with...
News 29.10.2026 Munich, Germany, and Schlieren-Zurich, Switzerland Preclinical program will evaluate Topadur’s proprietary, locally acting compounds, including clinical-stage TOP-N53, which target key disease processes in dystrophic Epidermolysis bullosa, a rare and debilitating genetic skin disorder DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and...
News 29.10.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited...